Drugs / Coenzyme Q10
Coenzyme Q10
Trials 40
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06361680 | Oct 2024 → Oct 2025 | type 1 diabetes mellitus | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT05945160 | Jan → Aug 2024 | vestibular disorder | The University of Texas Health Science Center at San Antonio | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT00860743 | Sep 2009 → Sep 2013 | sleep apnea syndrome | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06856447 | Jun 2024 → May 2025 overdue | colorectal cancer | toqa saad mohammed mohammed | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07668284 | Dec 2026 → Feb 2030 expected | anus cancer, cervical cancer, prostate cancer | University of Nebraska | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT00541164 | Sep 2007 → Jan 2013 | Charcot-Marie-Tooth disease | Memorial Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00247026 | Apr 2007 → ? | myelodysplastic syndrome | Hadassah Medical Organization | Withdrawn | No outcome recorded Stop: Business |
| Phase 210 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT06570811 | Aug 2024 → Mar 2025 | breast cancer, chemotherapy-induced toxicity | Damanhour University | Completed | Met primary |
| Phase 2 | NCT07096557 | Jan → Nov 2024 | pediatric systemic lupus erythematosus | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT05984745 | Oct 2023 → Jul 2025 overdue | NAFLD1 | Ain Shams University | Recruiting | No outcome recorded |
| Phase 2 | NCT05429229 | Nov 2021 → Dec 2023 | diabetic retinopathy, disorder of defective peroxisome oxidative status, dry eye syndrome | Adolfo Daniel Rodriguez-Carrizalez | Unknown | No outcome recorded |
| Phase 2 | NCT03111433 | Mar 2017 → Jan 2018 | type 1 diabetes mellitus | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT01319110 | Feb → Dec 2011 | cardiac arrest, sudden cardiac arrest | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00327756 | May 2006 → May 2009 | bipolar disorder, depressive disorder | National Institute of Mental Health (NIMH) | Withdrawn | No outcome recorded |
| Phase 2 | NCT00243932 | Apr 2005 → Mar 2008 | amyotrophic lateral sclerosis | Columbia University | Completed | Missed primary |
| Phase 2 | NCT00033189 | Sep 2001 → Jan 2005 | Duchenne muscular dystrophy | Cooperative International Neuromuscular Research Group | Completed | No outcome recorded |
| Phase 2 | NCT00004731 | Sep 1998 → Oct 2003 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2/32 trials · 1 met primary | ||||||
| Phase 2/3 | NCT05871086 | May → Dec 2023 | juvenile idiopathic arthritis | Nourhan Elsherif | Unknown | No outcome recorded |
| Phase 2/3 | NCT05293132 | Feb 2022 → Jun 2023 | infectious disease with sepsis | Ain Shams University | Completed | Met primary |
| Phase 34 trials · 1 met primary · 2 missed | ||||||
| Phase 3 | NCT06405204 | Jun → Dec 2024 | — | Beni-Suef University | Unknown | Met primary |
| Phase 3 | NCT05731596 | Jun 2023 → Feb 2024 | metabolic dysfunction-associated steatohepatitis | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT00740714 | Dec 2008 → Aug 2011 | Parkinson disease | Weill Medical College of Cornell University | Terminated | Missed primary |
| Phase 3 | NCT00180037 | Sep 2003 → Jun 2005 | Parkinson disease | Technical University Dresden | Completed | Missed primary |
| Phase 47 trials · 1 met primary | ||||||
| Phase 4 | NCT06743802 | Jan 2025 → Mar 2026 overdue | — | The Second Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT06452134 | Jul → Sep 2024 | alveolar periostitis, temporomandibular joint disorder | Zahra Nejati | Unknown | Met primary |
| Phase 4 | NCT06429345 | Jun → Oct 2024 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT04302532 | Jul → Sep 2020 | — | Karachi Medical and Dental College | Completed | No outcome recorded |
| Phase 4 | NCT03104998 | Aug 2017 → Mar 2018 | infertility disorder | PharmEvo Pvt Ltd | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02115581 | Sep 2006 → Mar 2008 | dilated cardiomyopathy | University of Tehran | Completed | Mixed |
| Phase 4 | NCT00307996 | Mar → Dec 2004 | chronic renal failure syndrome | University of Shizuoka | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT07317440 | Dec 2025 → Jun 2026 overdue | — | Tanta University | Not yet recruiting | No outcome recorded |
| — | NCT07252518 | Oct 2025 → Jul 2026 overdue | male infertility | Mst.Sumyara Khatun | Recruiting | No outcome recorded |
| — | NCT06661018 | Jan → Apr 2024 | ST-elevation myocardial infarction | Universitas Diponegoro | Completed | No outcome recorded |
| — | NCT06042738 | Mar → Nov 2021 | male infertility | Ondokuz Mayıs University | Completed | No outcome recorded |
| — | NCT04444349 | Feb 2021 → Dec 2025 overdue | cardiovascular disorder | Nanjing Medical University | Recruiting | No outcome recorded |
| — | NCT01925937 | Jun 2013 → Jan 2014 | congestive heart failure | Isfahan University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT01390389 | Jul 2011 → Jul 2012 | bipolar depression | Mclean Hospital | Completed | No outcome recorded |
| — | NCT01910766 | Jan 2010 → Jan 2013 | polycystic ovary syndrome | Mansoura University | Completed | No outcome recorded |
| — | NCT00716612 | Jan 2009 → Sep 2012 | statin toxicity | Hadassah Medical Organization | Completed | No outcome recorded |
| — | NCT00720369 | Jul 2008 → Mar 2010 | bipolar depression | Mclean Hospital | Completed | No outcome recorded |
| Comparator or background therapy23 trials | ||||||
| Phase 0 | NCT07841548 Comparator | Sep 2026 → Dec 2027 expected | ovarian dysfunction | Shi Yun | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06089395 Comparator | Jun 2024 → Aug 2025 | ovarian dysfunction | Shi Yun | Unknown | No outcome recorded |
| Phase 0 | NCT06342856 Comparator | Jun 2023 → Jun 2024 | oligospermia | Ain Shams University | Unknown | No outcome recorded |
| Phase 1 | NCT04091698 Comparator | Oct 2019 → Oct 2021 | lichen planus, oral | Cairo University | Unknown | No outcome recorded |
| Phase 1 | NCT00957216 Comparator | Apr 2008 → Aug 2009 | sporadic adult-onset ataxia of unknown etiology | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| Phase 1/2 | NCT02486796 Comparator | Feb 2016 → Mar 2017 | — | Midwestern Regional Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT05873673 Comparator | Jun 2023 → Mar 2025 overdue | odontogenic cyst | Fayoum University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04960215 Comparator | May 2021 → Feb 2022 | COVID-19, long COVID-19 | Aarhus University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01471652 Comparator | Mar 2012 → Feb 2013 | myalgic encephalomeyelitis/chronic fatigue syndrome | Columbia University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00328874 Comparator | May 2006 → Feb 2007 | progressive supranuclear palsy | German Parkinson Study Group (GPS) | Completed | No outcome recorded |
| Phase 2/3 | NCT07476443 Comparator | Apr 2026 → May 2027 expected | cisplatin toxicity | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT01126697 Comparator | Feb 2010 → Dec 2017 | Becker muscular dystrophy, Duchenne muscular dystrophy, limb-girdle muscular dystrophy | Cooperative International Neuromuscular Research Group | Completed | No outcome recorded |
| Phase 3 | NCT04216186 Comparator | Nov 2018 → Dec 2030 expected | attention deficit-hyperactivity disorder | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT00608881 Comparator | Mar 2008 → Nov 2014 | Huntington disease | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT00432744 Comparator | Jan 2007 → May 2013 | mitochondrial disease | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT05942027 Comparator | Jul 2023 → Jul 2026 overdue | chronic kidney disease | Tanta University | Recruiting | No outcome recorded |
| Phase 4 | NCT01026311 Comparator | Nov 2009 → Mar 2011 | statin toxicity | Richard Deichmann, MD | Completed | No outcome recorded |
| — | NCT06597682 Background | Mar 2025 → Jul 2027 expected | long COVID-19 | Huashan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07455890 Background | Jul 2024 → Jan 2026 | male infertility | Mst.Sumyara Khatun | Completed | No outcome recorded |
| — | NCT06576245 Background | Sep 2023 → Feb 2024 | dry eye syndrome | University of Seville | Completed | No outcome recorded |
| — | NCT03961087 Comparator | May 2019 → Jan 2020 | hepatic encephalopathy, intellectual disability | Zagazig University | Unknown | No outcome recorded |
| — | NCT03213769 Comparator | Jul 2017 → Jul 2018 | aphthous stomatitis | Cairo University | Unknown | No outcome recorded |
| — | NCT01140308 Comparator | Sep 2009 → Sep 2013 | statin toxicity | Hartford Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 18
| Date | Issuer | Release |
|---|---|---|
| 2026-07-15 | BPGbio | Results BPGbio Reports Encouraging Preliminary Data from Ongoing Phase 2 Study of BPM31510 in Newly Diagnosed Glioblastoma bpgbio.com ↗
Among patients evaluable per protocol (N=39), preliminary findings demonstrated a strong median overall survival (OS) of 19.3 months led by nearly 2X median OS compared to historical controls for the hardest-to-treat subgroup. |
| 2026-06-17 | BPGbio | Results BPGbio Presents Latest Clinical and Translational Findings Supporting BPM31510 in Primary CoQ10 Deficiency at Mito Med 2026 bpgbio.com ↗
Presentations highlight clinical outcomes in pediatric PCQD subjects and translational evidence supporting tissue delivery and mitochondrial metabolic correction |
| 2026-01-20 | BPGbio | Regulatory BPGbio Receives FDA Orphan Drug Designation for BPM31510 for the Treatment of Primary CoQ10 Deficiency bpgbio.com ↗
BPGbio, Inc ., a leading biology-first, AI-powered clinical-stage biopharma company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead candidate, BPM31510 , for the treatment of primary coenzyme Q10 (CoQ10) deficiency (PCQD). |
| 2025-12-16 | BPGbio | Results BPGbio Announces Publication of Pioneering Solid Tumor Study with BPM31510 IV using Patient Omics and Bayesian AI to Guide Clinical Development bpgbio.com ↗
Phase 1a/1b study in 97 patients demonstrates mitochondrial metabolic reprogramming induced by BPM31510-IV and supports advancement in multiple aggressive solid tumor indications. |
| 2025-11-03 | BPGbio | Results BPGbio to Present New Data on Immuno-Metabolic Reprogramming and Immunogenic Cell Death at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting bpgbio.com ↗ |
| 2025-10-16 | BPGbio | Results BPGbio Presents Phase 2 Glioblastoma Data on BPM31510 at ESMO 2025 bpgbio.com ↗ |
| 2025-06-18 | BPGbio | Results BPGbio Announces Presentation of Preliminary Clinical Data Of Investigational BPM31510 For Primary CoQ10 Deficiency bpgbio.com ↗
Dr. Modur’s presentation will detail that BPM31510 has been well-tolerated in all three PCQD patients treated so far with no serious adverse events or drug related adverse events reported during the course of the treatment. |
| 2025-04-25 | BPGbio | Results BPGbio Highlights Groundbreaking Data on BPM31510 for Mitochondrial Diseases at the Inaugural Mitochondrial Transplantation and Next Generation Therapeutics Conference bpgbio.com ↗
Using cutting-edge spatial quinomics techniques, BPGbio researchers show that BPM31510 significantly increased CoQ10 levels across multiple tissues—including the brain, kidney, muscle, and heart—in Coq4 KI/KI mice (a mouse model of CoQ deficiency) in collaboration with Dr. Catarina Quinzii of Columbia University. |
| 2024-11-21 | BPGbio | Results BPGbio to Present New Data on Novel Glioblastoma Therapies at SNO 2024 bpgbio.com ↗
The study demonstrates BPM31510’s ability to effectively target and diminish cancer cells while selectively allowing the growth of healthy brain cells, an effect that standard treatments fail to achieve. |
| 2024-11-07 | BPGbio | Results BPGbio to Present Transformative Immuno-Oncology Research on BPM31510 and BRG399 at SITC 2024 bpgbio.com ↗
In the first study, titled “The Anti-tumor Response of BPM31510 is Associated with Immune Cell Regulation in the Tumor Microenvironment,” researchers showed that BPM31510 significantly increases reactive oxygen species (ROS) levels in cancer cells, leading to cell death across multiple cancer types. |
| 2024-10-31 | BPGbio | Regulatory BPGbio Receives FDA Rare Pediatric Disease Designation for its Investigational Treatment for Epidermolysis Bullosa bpgbio.com ↗ |
| 2024-10-23 | BPGbio | Results BPGbio to Present New Data on BPM31510 and Novel Quinomics Technology for Treatment of Primary CoQ10 Deficiency at MitoCon 2024 bpgbio.com ↗
BPM31510 outperforms traditional oral CoQ10 in treating mitochondrial dysfunction |
| 2024-09-30 | BPGbio | Regulatory BPGbio Receives FDA Rare Pediatric Disease Designation for its Potential Treatment for Primary Coenzyme Q10 Deficiency bpgbio.com ↗ |
| 2024-09-12 | BPGbio | Results BPGbio Presents Phase 2b BPM31510 Glioblastoma Trial-in-Progress Update and Pioneering Comprehensive Quinomics Assessment at the ESMO Congress 2024 bpgbio.com ↗
“The preliminary results from the ongoing clinical trial support our biology-first, AI-driven approach, optimizing patient selection and streamlining drug development,” said Niven R. Narain , Ph.D., President and CEO of BPGbio, Inc. |
| 2024-08-14 | BPGbio | Results The Power of NAi – De-risking Clinical Trials Increasing the predictability of clinical trial outcomes bpgbio.com ↗
Leveraging our multiomic data we could better understand how BPM31510 induced a shift in metabolism and see that its effect was limited to those with more aggressive tumors. |
| 2024-04-05 | BPGbio | Results BPGbio Presents Key Advances in its Oncology Pipeline related to the NAi Interrogative Biology Platform bpgbio.com ↗
New data further validating the mitochondrial-centric effect of BPM31510 on the immune system. |
| 2024-01-17 | BPGbio | Results BPGbio Presents Updated Phase 2a Clinical Results Demonstrating Benefit of BPM31510 in Combination with Chemotherapy in Pancreatic Cancer at ASCO GI bpgbio.com ↗
Among study participants, median progression free survival was 7.2 months (range: 3.8 months – 10.5 months), twice the observed median progression free survival (3.6 months) reported in patients receiving treatment with gemcitabine alone . |
| 2023-12-14 | Indena S.p.A | Results New clinical evidences confirm better muscle uptake in individuals after supplementation with coenzyme Q10 Phytosome™ indena.com ↗
A recently issued, new ex-vivo study demonstrates that CoQ10 Phytosome™, i.e. Indena’s UBIQSOME ® , optimizes cellular ubiquinone uptake in muscle cells in comparison to unformulated CoQ10. |
All press releases naming this drug 20 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 71 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CoenzymeQ10 | “It consists of a preservative-free eye drop composed of 100 mg cross-linked hyaluronic acid, 100 mg coenzyme Q10, 500 mg vitamin E TPGS (D-alpha-tocopheryl polyethylene glycol...” NCT05429229 ↗71“food supplement containing 2000 mg L-carnitine, 2000 mg fructose, 932 mg acetyl L-carnitine, 225 mg vitamin C, 115 mg citric acid, 50 mg coenzyme Q10, 14 mg zinc, 115 µg...” NCT06042738 ↗ “Coenzyme Q10 (CoQ10) supplementation is the most popular therapy for statin myalgia among both physicians and patients despite limited and conflicting evidence of its efficacy.” PMID 25545331 ↗ Dec 2014 “Coenzyme Q10 (CoQ10)-an essential cofactor for energy production with major antioxidant properties-is commonly used to support spermatogenesis in idiopathic male infertility.” PMID 34070761 ↗ May 2021 “Coenzyme Q10 Impact on Ovarian Reserve Measures and the Intra-Cytoplasmic Sperm Injection (ICSI) Outcomes in Women with Poor Ovarian Response: A Randomized Controlled Study.” PMID 41800295 ↗ Mar 2026 “Patients will receive CoenzymeQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first).” NCT01319110 ↗ “Coenzyme Q10 (CoQ10) is a natural mitochondrial electron carrier and a powerful lipophilic antioxidant located in almost all cell membranes and plasma lipoproteins.” NCT05871086 ↗ “Coenzyme Q10 (CoQ10) is an organic molecule can be found in both reduced (ubiquinol) and oxidised (ubiquinone) forms in mitochondria and cell membranes.” NCT05942027 ↗ “The study evaluates the effect of coenzyme q 10 on ovulation and subsequent pregnancy in women with polycystic ovarian syndrome.” NCT04302532 ↗ “Coenzyme Q10 in the Treatment of Attention Deficit Hyperactivity Disorder in Children: A Randomized Controlled Trial.” PMID 34819012 ↗ 2022 “Coenzyme Q10 (CoQ10) or ubiquinone is a lipid-soluble vitamin-like antioxidant naturally found in the diet” NCT04091698 ↗ |
| Known as | CoQ10 | “The study will also examine whether the food supplement Coenzyme Q10 (CoQ10) improves mitochondrial function and symptoms such as depressed mood, low energy, anxiety or...” NCT00327756 ↗16“Coenzyme Q10 (CoQ10) or ubiquinone is a lipid-soluble and vitamin-like compound, which acts as a pivotal cofactor in the mitochondrial respiratory chain in addition to its role...” NCT05984745 ↗ “Coenzyme Q(10) (CoQ(10)) is an electron acceptor bridging mitochondrial complexes I and II/III and a potent antioxidant that consistently partially recovers the function of...” PMID 17502459 ↗ May 2007 “This study explores whether coenzyme Q10 (CoQ10), a nutritional supplement with antioxidant and anti-inflammatory properties, can reduce pain after video-assisted thoracoscopic...” PMID 41025845 ↗ Sep 2025 “Coenzyme Q10 (CoQ10)-an essential cofactor for energy production with major antioxidant properties-is commonly used to support spermatogenesis in idiopathic male infertility.” PMID 34070761 ↗ May 2021 “Coenzyme Q10 (CoQ10), an antioxidant that supports mitochondrial function, has been shown in preclinical Parkinson disease (PD) models to reduce the loss of dopamine neurons” PMID 24664227 ↗ May 2014 “Coenzyme Q10 (CoQ10) is a natural mitochondrial electron carrier and a powerful lipophilic antioxidant located in almost all cell membranes and plasma lipoproteins.” NCT05871086 ↗ “This study investigated whether Coenzyme Q10 (CoQ10) could mitigate paclitaxel-induced adverse events and improve treatment tolerability.” PMID 42401951 ↗ Jul 2026 “CoenzymeQ10 will be given in 10 mg/kg daily up to 400 mg. Then a draw of CoQ10 troughs every three months will be performed.” NCT00432744 ↗ “Coenzyme Q10 (CoQ10) or ubiquinone is a lipid-soluble vitamin-like antioxidant naturally found in the diet” NCT04091698 ↗ “Coenzyme Q10 (CoQ10) is an oil-soluble, vitamin-like substance primarily present in mitochondria.” NCT06856447 ↗ |
| Known as | nanoQuinon | “to Assess the Safety, Tolerability, and Immediate Biological Effects of Coenzyme Q10 - nanoQuinon® in Progressive Supranuclear Palsy” NCT00328874 ↗ |
| Known as | ubiquinol | “Coenzyme Q10 (ubiquinol) is an antioxidant that may play a significant role in the treatment of Attention Deficit Hyperactivity Disorder.” PMID 34819012 ↗ 20221“coenzyme Q10 (coQ10 or ubiquinol) versus topical corticosteroids” PMID 37480004 ↗ Jul 2023 |
| Known as | ubiquinone | “Coenzyme Q10 (CoQ10) or ubiquinone is a lipid-soluble and vitamin-like compound, which acts as a pivotal cofactor in the mitochondrial respiratory chain in addition to its role...” NCT05984745 ↗1“Coenzyme Q10 (CoQ10) or ubiquinone is a lipid-soluble vitamin-like antioxidant naturally found in the diet” NCT04091698 ↗ |
| Modality | Other / unclassified | “nutritional supplement Coenzyme Q10” NCT00033189 ↗ |
| Route | Oral | “antioxidant and mitochondrial cofactor, given in capsules three times daily” NCT00243932 ↗ |